ABM Therapeutics
An innovative drug discovery and development company focusing on small molecule targeted therapy for the possible treatments of brain cancers.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor investor investor investor investor | €0.0 | round | |
$30.0m | Series B | ||
| Total Funding | 000k | ||
Related Content
ABM Therapeutics is an innovative drug discovery company specializing in small molecule targeted therapies for brain cancers, including glioblastoma multiforme (GBM), and brain metastasis originating from lung cancer, breast cancer, and melanoma. Founded in 2015 by a team of seasoned scientists and entrepreneurs with over 20 years of experience in neurological drug development and enterprise management, ABM Therapeutics operates in the biotechnology and pharmaceutical sectors. The company serves patients worldwide who are in need of advanced treatments for brain-related cancers. ABM Therapeutics generates revenue through the development and commercialization of its proprietary drug pipeline, which is built internally and through collaborations with Contract Research Organizations (CROs) and strategic partners. The business model focuses on both preclinical and clinical stage asset acquisitions to enhance its brain medicine research and development platform. ABM Therapeutics is committed to delivering best-in-class and first-in-class medicines to improve patient outcomes.
Keywords: small molecule therapy, brain cancer, GBM, brain metastasis, lung cancer, breast cancer, melanoma, drug discovery, biotechnology, pharmaceutical.